{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:18:07Z","timestamp":1790961487703,"version":"4.1.0"},"reference-count":126,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>Bone turnover markers (BTMs) are useful in clinical practice as they are inexpensive, and they have proven useful for treatment monitoring and identification of poor adherence. BTMs cannot be used in individual patients for identifying accelerated bone loss or an increase in fracture risk or in deciding on the optimal therapy. They are useful for monitoring both anti-resorptive and anabolic treatment. Response can be defined as a result that exceeds an absolute target, or by a change greater than the least significant change; if such a response is not present, then poor compliance or secondary osteoporosis are likely causes. A baseline BTM measurement is not always made; in that case, a value of BTM on anti-resorptive treatment that is low or low normal or above the reference interval for anabolic therapy may be taken to indicate a satisfactory response. We provide an approach to using these bone turnover markers in clinical practice by describing algorithms for anti-resorptive and anabolic therapy and describing the changes we observe in the clinical practice setting.<\/jats:p>","DOI":"10.1530\/eje-17-0585","type":"journal-article","created":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T20:20:14Z","timestamp":1508358014000},"page":"R19-R31","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":133,"title":["DIAGNOSIS OF ENDOCRINE DISEASE: Bone turnover markers: are they clinically useful?"],"prefix":"10.1093","volume":"178","author":[{"given":"Richard","family":"Eastell","sequence":"first","affiliation":[{"name":"1Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Pigott","sequence":"additional","affiliation":[{"name":"2Metabolic Bone Centre, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Gossiel","sequence":"additional","affiliation":[{"name":"1Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim E","family":"Naylor","sequence":"additional","affiliation":[{"name":"1Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S","family":"Walsh","sequence":"additional","affiliation":[{"name":"1Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola F A","family":"Peel","sequence":"additional","affiliation":[{"name":"2Metabolic Bone Centre, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"ref251","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","year":"2015","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref221","first-page":"34","article-title":"Clinical usefulness of bone turnover marker concentrations in osteoporosis","volume":"467","year":"2016","journal-title":"Clinica Chimica Acta"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s00198-010-1372-5","article-title":"Adherence and profile of non-persistence in patients treated for osteoporosis \u2013 a large-scale, long-term retrospective study in The Netherlands","volume":"22","year":"2011","journal-title":"Osteoporosis International"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/jc.2016-3170","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report","volume":"102","year":"2017","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00198-014-2646-0","article-title":"PINP as a biological response marker during teriparatide treatment for osteoporosis","volume":"25","year":"2014","journal-title":"Osteoporosis International"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1359\/jbmr.1997.12.1.59","article-title":"Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis","volume":"12","year":"1997","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1359\/jbmr.07090b","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis \u2013 response","volume":"22","year":"2007","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1251","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.bone.2010.12.006","article-title":"PINP as an aid for monitoring patients treated with teriparatide","volume":"48","year":"2011","journal-title":"Bone"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/jbmr.2889","article-title":"Urinary N-telopeptide and rate of bone loss over the menopause transition and early postmenopause","volume":"31","year":"2016","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1191","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","year":"2006","journal-title":"JAMA"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1210\/jcem-67-4-741","article-title":"Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers","volume":"67","year":"1988","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00198-013-2426-2","article-title":"An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide","volume":"25","year":"2014","journal-title":"Osteoporosis International"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","year":"2015","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/jamainternmed.2014.1232","article-title":"Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study","volume":"174","year":"2014","journal-title":"JAMA Internal Medicine"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/jbmr.1644","article-title":"Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","year":"2012","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1007\/s00198-016-3573-z","article-title":"Eastell R. Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia","volume":"27","year":"2016","journal-title":"Osteoporosis International"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00198-013-2426-2","article-title":"An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide","volume":"25","year":"2014","journal-title":"Osteoporosis International"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s00198-010-1372-5","article-title":"Adherence and profile of non-persistence in patients treated for osteoporosis \u2013 a large-scale, long-term retrospective study in The Netherlands","volume":"22","year":"2011","journal-title":"Osteoporosis International"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/030079905X75096","article-title":"Development of an algorithm for using PINP to monitor treatment of patients with teriparatide","volume":"22","year":"2006","journal-title":"Current Medical Research and Opinion"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00198-005-2025-y","article-title":"Changes in bone mass and bone turnover following tibial shaft fracture","volume":"17","year":"2006","journal-title":"Osteoporosis International"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s001980050247","article-title":"Changes in bone mass and bone turnover following ankle fracture","volume":"10","year":"1999","journal-title":"Osteoporosis International"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.bone.2012.02.003","article-title":"Reference intervals of bone turnover markers in healthy premenopausal women: results from a cross-sectional European study","volume":"50","year":"2012","journal-title":"Bone"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1359\/jbmr.090310","article-title":"Effects of yearly zoledronic acid 5\u2009mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis","volume":"24","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00774-012-0392-y","article-title":"Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition)","volume":"31","year":"2013","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1359\/jbmr.1997.12.1.59","article-title":"Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis","volume":"12","year":"1997","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/jbmr.2361","article-title":"Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study","volume":"30","year":"2015","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bone.2006.02.003","article-title":"Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover","volume":"39","year":"2006","journal-title":"Bone"},{"key":"ref141","first-page":"220","article-title":"Official positions for FRAX(R) clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(R).","volume":"14","year":"2011","journal-title":"Journal of Clinical Densitometry"},{"key":"ref1181","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research.","volume":"31","year":"2016","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s40265-017-0780-7","article-title":"Abaloparatide: first global approval","volume":"77","year":"2017","journal-title":"Drugs"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1007\/s00198-013-2386-6","article-title":"Adherence to raloxifene therapy: assessment methods and relationship with efficacy","volume":"24","year":"2013","journal-title":"Osteoporosis International"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1210\/jc.2007-1508","article-title":"Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk","volume":"93","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1359\/jbmr.080703","article-title":"Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States","volume":"24","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis","volume":"26","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1373\/clinchem.2010.148841","article-title":"Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care","volume":"57","year":"2011","journal-title":"Clinical Chemistry"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","year":"2015","journal-title":"Osteoporosis International"},{"key":"ref1031","first-page":"91","article-title":"The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis","volume":"35","year":"2016","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"ref711","first-page":"67","article-title":"Changes in serial results","volume-title":"Biological Variation: From Principles to Practice","year":"2001"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1359\/jbmr.080703","article-title":"Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States","volume":"24","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/jbmr.2847","article-title":"Potential usefulness of BMD and bone turnover monitoring of zoledronic acid therapy among women with osteoporosis: secondary analysis of randomized controlled trial data","volume":"31","year":"2016","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.bone.2009.07.091","article-title":"Rapid and robust response of biochemical markers of bone formation to teriparatide therapy","volume":"45","year":"2009","journal-title":"Bone"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/jbmr.2889","article-title":"Urinary N-telopeptide and rate of bone loss over the menopause transition and early postmenopause","volume":"31","year":"2016","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1007\/s00198-016-3675-7","article-title":"Association of bone turnover markers with volumetric bone loss, periosteal apposition, and fracture risk in older men and women: the AGES-Reykjavik Longitudinal Study","volume":"27","year":"2016","journal-title":"Osteoporosis International"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1373\/clinchem.2010.148841","article-title":"Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care","volume":"57","year":"2011","journal-title":"Clinical Chemistry"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","article-title":"Treatment failure in osteoporosis","volume":"23","year":"2012","journal-title":"Osteoporosis International"},{"key":"ref1221","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bone.2007.12.218","article-title":"Establishing a reference range for bone turnover markers in young, healthy women","volume":"42","year":"2008","journal-title":"Bone"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.bone.2009.07.091","article-title":"Rapid and robust response of biochemical markers of bone formation to teriparatide therapy","volume":"45","year":"2009","journal-title":"Bone"},{"key":"ref1271","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00774-012-0392-y","article-title":"Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition)","volume":"31","year":"2013","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/jbmr.1644","article-title":"Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","year":"2012","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.bone.2012.02.003","article-title":"Reference intervals of bone turnover markers in healthy premenopausal women: results from a cross-sectional European study","volume":"50","year":"2012","journal-title":"Bone"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/jbmr.2847","article-title":"Potential usefulness of BMD and bone turnover monitoring of zoledronic acid therapy among women with osteoporosis: secondary analysis of randomized controlled trial data","volume":"31","year":"2016","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jocd.2017.06.020","article-title":"Bone turnover markers: use in fracture prediction","volume":"20","year":"2017","journal-title":"Journal of Clinical Densitometry"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jocd.2017.06.020","article-title":"Bone turnover markers: use in fracture prediction","volume":"20","year":"2017","journal-title":"Journal of Clinical Densitometry"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial","volume":"19","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","article-title":"Treatment failure in osteoporosis","volume":"23","year":"2012","journal-title":"Osteoporosis International"},{"key":"ref1161","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/jbmr.2023","article-title":"Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW)","volume":"29","year":"2014","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1210\/jc.2007-1508","article-title":"Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk","volume":"93","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1007\/s00198-016-3581-z","article-title":"A retrospective analysis of nonresponse to daily teriparatide treatment.","volume":"27","year":"2016","journal-title":"Osteoporosis International"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/clinchem\/47.8.1410","article-title":"Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-tlopeptides","volume":"47","year":"2001","journal-title":"Clinical Chemistry"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1210\/jcem-67-4-741","article-title":"Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers","volume":"67","year":"1988","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","year":"2011","journal-title":"Osteoporosis International"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","year":"2003","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00198-017-3906-6","article-title":"International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates","volume":"28","year":"2017","journal-title":"Osteoporosis International"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"16069","DOI":"10.1038\/nrdp.2016.69","article-title":"Postmenopausal osteoporosis","volume":"2","year":"2016","journal-title":"Nature Reviews Disease Primers"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/clinchem\/47.8.1410","article-title":"Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-tlopeptides","volume":"47","year":"2001","journal-title":"Clinical Chemistry"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/jc.2016-3170","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report","volume":"102","year":"2017","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/jbmr.2023","article-title":"Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW)","volume":"29","year":"2014","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1007\/s00198-016-3573-z","article-title":"Eastell R. Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia","volume":"27","year":"2016","journal-title":"Osteoporosis International"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s001980050246","article-title":"Changes in bone mass and bone turnover following distal forearm fracture","volume":"10","year":"1999","journal-title":"Osteoporosis International"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00198-005-2025-y","article-title":"Changes in bone mass and bone turnover following tibial shaft fracture","volume":"17","year":"2006","journal-title":"Osteoporosis International"},{"key":"ref851","first-page":"21","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.","volume":"27","year":"2015","journal-title":"Osteoporos International"},{"key":"ref861","first-page":"34","article-title":"Clinical usefulness of bone turnover marker concentrations in osteoporosis","volume":"467","year":"2016","journal-title":"Clinica Chimica Acta"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s001980050247","article-title":"Changes in bone mass and bone turnover following ankle fracture","volume":"10","year":"1999","journal-title":"Osteoporosis International"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s10354-012-0133-9","article-title":"Biomarkers of bone turnover in diagnosis and therapy of osteoporosis: a consensus advice from an Austrian working group","volume":"162","year":"2012","journal-title":"Wiener Medizinische Wochenschrift"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s40265-017-0780-7","article-title":"Abaloparatide: first global approval","volume":"77","year":"2017","journal-title":"Drugs"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s00198-017-4082-4","article-title":"Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability","volume":"28","year":"2017","journal-title":"Osteoporosis International"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1359\/jbmr.2000.15.7.1398","article-title":"Biochemical markers as predictors of rates of bone loss after menopause","volume":"15","year":"2000","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/1874325001105010032","article-title":"Early changes in bone specific turnover markers during the healing process after vertebral fracture","volume":"5","year":"2011","journal-title":"Open Orthopaedics Journal"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s001980050246","article-title":"Changes in bone mass and bone turnover following distal forearm fracture","volume":"10","year":"1999","journal-title":"Osteoporosis International"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/jbmr.1864","article-title":"BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate","volume":"28","year":"2013","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/jamainternmed.2014.1232","article-title":"Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study","volume":"174","year":"2014","journal-title":"JAMA Internal Medicine"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1359\/JBMR.0301231","article-title":"Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate","volume":"19","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","year":"2003","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis","volume":"26","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00198-014-2646-0","article-title":"PINP as a biological response marker during teriparatide treatment for osteoporosis","volume":"25","year":"2014","journal-title":"Osteoporosis International"},{"key":"ref1171","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1359\/JBMR.0301231","article-title":"Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate","volume":"19","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","year":"2016","journal-title":"JAMA"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bone.2007.12.218","article-title":"Establishing a reference range for bone turnover markers in young, healthy women","volume":"42","year":"2008","journal-title":"Bone"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","year":"2005","journal-title":"Archives of Internal Medicine"},{"key":"ref71","first-page":"67","article-title":"Changes in serial results","volume-title":"Biological Variation: From Principles to Practice","year":"2001"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1210\/jc.2015-2957","article-title":"Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women?","volume":"100","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s00198-017-4082-4","article-title":"Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability","volume":"28","year":"2017","journal-title":"Osteoporosis International"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","year":"2015","journal-title":"Osteoporosis International"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1359\/jbmr.07090b","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis \u2013 response","volume":"22","year":"2007","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","year":"2016","journal-title":"JAMA"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1359\/jbmr.2000.15.7.1398","article-title":"Biochemical markers as predictors of rates of bone loss after menopause","volume":"15","year":"2000","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial","volume":"19","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1359\/jbmr.090310","article-title":"Effects of yearly zoledronic acid 5\u2009mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis","volume":"24","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","year":"2006","journal-title":"JAMA"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00223-014-9842-y","article-title":"A meta-analysis of reference markers of bone turnover for prediction of fracture","volume":"94","year":"2014","journal-title":"Calcified Tissue International"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/1874325001105010032","article-title":"Early changes in bone specific turnover markers during the healing process after vertebral fracture","volume":"5","year":"2011","journal-title":"Open Orthopaedics Journal"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1359\/JBMR.051018","article-title":"Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial","volume":"21","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref391","first-page":"91","article-title":"The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis","volume":"35","year":"2016","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1007\/s00198-013-2386-6","article-title":"Adherence to raloxifene therapy: assessment methods and relationship with efficacy","volume":"24","year":"2013","journal-title":"Osteoporosis International"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1210\/jc.2015-2957","article-title":"Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women?","volume":"100","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research.","volume":"31","year":"2016","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1007\/s00198-016-3581-z","article-title":"A retrospective analysis of nonresponse to daily teriparatide treatment.","volume":"27","year":"2016","journal-title":"Osteoporosis International"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/jbmr.1864","article-title":"BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate","volume":"28","year":"2013","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s10354-012-0133-9","article-title":"Biomarkers of bone turnover in diagnosis and therapy of osteoporosis: a consensus advice from an Austrian working group","volume":"162","year":"2012","journal-title":"Wiener Medizinische Wochenschrift"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/jbmr.2361","article-title":"Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study","volume":"30","year":"2015","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref211","first-page":"21","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.","volume":"27","year":"2015","journal-title":"Osteoporos International"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.bone.2010.12.006","article-title":"PINP as an aid for monitoring patients treated with teriparatide","volume":"48","year":"2011","journal-title":"Bone"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00223-014-9842-y","article-title":"A meta-analysis of reference markers of bone turnover for prediction of fracture","volume":"94","year":"2014","journal-title":"Calcified Tissue International"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bone.2006.02.003","article-title":"Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover","volume":"39","year":"2006","journal-title":"Bone"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","year":"2005","journal-title":"Archives of Internal Medicine"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1007\/s00198-016-3675-7","article-title":"Association of bone turnover markers with volumetric bone loss, periosteal apposition, and fracture risk in older men and women: the AGES-Reykjavik Longitudinal Study","volume":"27","year":"2016","journal-title":"Osteoporosis International"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1359\/JBMR.051018","article-title":"Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial","volume":"21","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","year":"2011","journal-title":"Osteoporosis International"},{"key":"ref781","first-page":"220","article-title":"Official positions for FRAX(R) clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(R).","volume":"14","year":"2011","journal-title":"Journal of Clinical Densitometry"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/030079905X75096","article-title":"Development of an algorithm for using PINP to monitor treatment of patients with teriparatide","volume":"22","year":"2006","journal-title":"Current Medical Research and Opinion"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"16069","DOI":"10.1038\/nrdp.2016.69","article-title":"Postmenopausal osteoporosis","volume":"2","year":"2016","journal-title":"Nature Reviews Disease Primers"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00198-017-3906-6","article-title":"International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates","volume":"28","year":"2017","journal-title":"Osteoporosis International"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/178\/1\/EJE-17-0585.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1530\/EJE-17-0585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T17:32:13Z","timestamp":1719509533000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/178\/1\/R19\/6655261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":126,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/eje-17-0585","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}